Novartis' Zia On Momentum Amid Policy Strain In India
Executive Summary
As Novartis continues to battle Glivec-related pain in India, its country president Jawed Zia tells Scrip that the Swiss multinational has been hit "particularly hard" after the government withdrew customs duty exemptions on more than 70 drugs including imatinib mesylate earlier this year.
You may also be interested in...
Novartis Rejiggers Pharma To Favor Oncology
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.
India's New IPR Policy: Balanced And Evolving?
India new National Intellectual Property Rights (IPR) policy appears to have steered clear of a host of prickly issues pertaining to the pharmaceutical industry for now while standing firm on the need for "strong measures" against attempts to treat generic drugs as "spurious or counterfeit".
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.